Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Jeanne Ford is active.

Publication


Featured researches published by Jeanne Ford.


Biochemical Pharmacology | 1991

Effect of the calmodulin inhibitor trifluoperazine on phosphorylation of P-glycoprotein and topoisomerase II: relationship to modulation of subcellular distribution, DNA damage and cytotoxicity of doxorubicin in multidrug resistant L1210 mouse leukemia cells.

Ram Ganapathi; Narayana Kamath; Andreas I. Constantinou; Dale Grabowski; Jeanne Ford; Austin Anderson

The results from the present study using the sensitive and progressively DOX resistant L1210 model system demonstrated that the effects of TFP are not due to redistribution of DOX to the nucleus, and modulation of cytotoxicity is related to effects on DOX-induced DNA strand breaks. Although TFP affects phosphorylation of PGP and TOPO II (R2 greater than R1), the comparable DNA strand breaks at lower DOX levels with TFP in the resistant sublines suggest that modulation of TOPO II function related to drug-induced DNA damage by calmodulin-mediated events may be an important mode of action.


Cancer Genetics and Cytogenetics | 1996

Acquisition of doxorubicin resistance in human leukemia HL-60 cells is reproducibly associated with 7q21 chromosomal anomalies

Ram Ganapathi; Gerald A. Hoeltge; Graham Casey; Dale Grabowski; Rosemary Neelon; Jeanne Ford

Tumor cell resistance to doxorubicin (DOX) is usually associated with the overexpression of P-glycoprotein (PGP) in model systems. We have characterized the karyotypic changes in two sublines of HL-60 cells which differ in the induction of differentiation by retinoic acid. The parental sublines, designated HL-60A/S and HL-60Y/S, were selected in increasing concentrations of 0.025-0.1 micrograms/mL DOX. Monosomy 8 in HL-60Y/S was the only karyotypic difference prior to DOX exposure. Both sublines acquired 7q+ markers upon exposure to DOX. In HL-60Y/S, and add(7)(q21) replaced one homologue at 0.025 micrograms/mL DOX, and an add(7)(q32) appeared which replaced the other normal 7 at 0.05 micrograms/mL DOX. The HL-60A/S cells acquired an add(7)(q21) at 0.025 micrograms/mL DOX. The 7q+ abnormalities involved breakpoints in the midregion of 7q. The overexpression of phosphorylated PGP in immunoprecipitates with C-219 antibody was identified in both sublines of DOX-resistant HL-60 cells with 7q+ abnormalities, and this is consistent with the location of mdr-1 sequences to 7q21-21.1. Also, analysis of RNA from parental-sensitive and DOX-resistant sublines by reverse transcriptase-polymerase chain reaction revealed: a) comparable expression of multidrug resistance related protein (MPR) in sensitive and resistant sublines; and b) overexpression of mdr-1 only in the DOX-resistant sublines. Thus, the selection of DOX resistance in two sublines of HL-60 cells which differ in their response to retinoic acid-induced myeloid differentiation is reproducibly associated with overexpression of mdr-1 versus MRP.


British Journal of Cancer | 1993

Calmodulin inhibitor trifluoperazine in combination with doxorubicin induces the selection of tumour cells with the multidrug resistant phenotype

Narayana Kamath; Dale Grabowski; Jeanne Ford; R. Ganapathi

Trifluoperazine (TFP) is effective in modulating DNA damage/repair in doxorubicin (DOX) treated cells. In the present study we have characterised the resistance phenotype of parental sensitive L1210 mouse leukaemia cells (L1210/S) adapted to grow in the presence of 0.017 microns DOX+5 microM TFP (L1210/DT). Although with prolonged exposure, 0.017 microM DOX alone produced < 35% cell kill in L1210/S cells, similar cytotoxicity was achieved at 0.43 microM DOX in L1210/S cells selected in the presence of 0.017 microM DOX+5 microM TFP. L1210/DT cells were > 30-fold resistant to DOX following a 3 h drug exposure in a soft agar colony assay. In contrast, DOX sensitivity in cells adapted to grow in 5 microM TFP alone was comparable to L1210/S cells. Resistance to other inhibitors of topoisomerase II in L1210/DT cells was > 30-fold to etoposide and > 6-fold to amsacrine. The levels of the 170 kDa and 180 kDa isoforms of topoisomerase II in an immunoblot were comparable between the L1210/S and L1210/DT cells. Cross resistance to vincristine in the L1210/DT cells was accompanied by the overexpression of plasma membrane P-glycoprotein. Although a 1.5-2-fold decrease in accumulation of etoposide and DOX was observed in the L1210/DT cells, drug levels for equivalent DNA damage in the alkaline elution assay were > 5-fold higher in the L1210/DT versus L1210/S cells. No abrogation in the modulating effects of TFP on DOX, VP-16 or amsacrine induced cytotoxicity was apparent in the L1210/DT cells. Results suggest that: (a) TFP in combination with low concentrations DOX can induce the selection of cells with the multidrug resistant phenotype; and (b) characteristics of cells selected for resistance to DOX or DOX plus TFP are comparable.


Biochemical Pharmacology | 1992

Overexpression of P-glycoprotein and alterations in topoisomerase II in P388 mouse leukemia cells selected in vivo for resistance to mitoxantrone

Narayana Kamath; Dale Grabowski; Jeanne Ford; Donna Kerrigan; Yves Pommier; Ram Ganapathi


Molecular Pharmacology | 1991

Relationship between expression of P-glycoprotein and efficacy of trifluoperazine in multidrug-resistant cells.

Ram Ganapathi; Tien Kuo; Larry Teeter; Dale Grabowski; Jeanne Ford


Cancer communications | 1989

Progressive resistance to doxorubicin in mouse leukemia L1210 cells with multidrug resistance phenotype: reductions in drug-induced topoisomerase II-mediated DNA cleavage.

Ganapathi R; Dale Grabowski; Jeanne Ford; Heiss C; Kerrigan D; Pommier Y


Biochemical and Biophysical Research Communications | 1993

Altered Phosphorylation, Biosynthesis and Degradation of the 170 kDa Isoform of Topoisomerase II in Amsacrine-Resistant Human Leukemia Cells

Ram Ganapathi; Leonard A. Zwelling; Andreas I. Constantinou; Jeanne Ford; Dale Grabowski


Cancer Research | 1993

Selective Enhancement of Vincristine Cytotoxicity in Multidrug-resistant Tumor Cells by Dilantin (Phenytoin)

Ram Ganapathi; Aleck Hercbergs; Dale Grabowski; Jeanne Ford


Oncology Research | 1995

Drastic reduction of topoisomerase IIα associated with major acquired resistance to topoisomerase II active agents but minor perturbations of cell growth

Shinya Hashimoto; Satadal Chatterjee; Geetha B. Ranjit; Chenyen Bao; Jeanne Ford; Ram Ganapathi; Sosamma J. Berger; Nathan A. Berger


Cancer communications | 1991

Trifluoperazine modulation of resistance to the topoisomerase II inhibitor etoposide in doxorubicin resistant L1210 murine leukemia cells

Narayana Kamath; Dale Grabowski; Jeanne Ford; Drake F; Kerrigan D; Pommier Y; Ganapathi R

Collaboration


Dive into the Jeanne Ford's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Geetha B. Ranjit

Case Western Reserve University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Nathan A. Berger

Case Western Reserve University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Satadal Chatterjee

Case Western Reserve University

View shared research outputs
Top Co-Authors

Avatar

Shinya Hashimoto

Case Western Reserve University

View shared research outputs
Top Co-Authors

Avatar

Sosamma J. Berger

Case Western Reserve University

View shared research outputs
Researchain Logo
Decentralizing Knowledge